Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Lithuania,United Kingdom,Israel,Austria,Sweden,Poland,Hungary,Spain,Germany,Portugal
nct
Update Il y a 5 ans
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy. The study will provide information for doctors on how to manage the transfer from methotrexate to the biologic agent ustekinumab. The study is designed to compare two methods of transferring patients from methotrexate to ustekinumab. The two methods being compared are discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
Country
Austria
,
Belgium
,
Bulgaria
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Israel
,
Lithuania
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Slovakia
,
Spain
,
Sweden
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.
Country
Austria
,
Belgium
,
Czech Republic
,
Estonia
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Lithuania
,
Poland
,
Portugal
,
Serbia
,
South Africa
,
Spain
,
Sweden
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
1